erevnon Posted - 2 weeks ago

Needham reiterates Pliant Therapeutics $PLRX at Buy and a maintains price target of https://marketsblock.com/stock-upgrades-and-downgrades/

Stock_Titan Posted - 3 weeks ago

$PLRX Pliant Therapeutics to Participate in Upcoming Investor Events https://www.stocktitan.net/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-v675ghkwkp63.html

Stock_Titan Posted - 03/27/24

$PLRX Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference https://www.stocktitan.net/news/PLRX/pliant-therapeutics-announces-upcoming-presentations-at-the-2024-j0u9t88yf58t.html

Stock_Titan Posted - 1 month ago

$PLRX Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis https://www.stocktitan.net/news/PLRX/pliant-therapeutics-announces-accelerated-bexotegrast-development-m6r4rg1numqj.html

Quantumup Posted - 1 month ago

RBC raised⬆️PT $PLRX $54 was $50/Outperform~believes core value driver remains Bexo's prospects in IPF, where investors may have lost focus. Analysis suggests mkt opp for Bexo' in IPF, an indication somewhat de-risked/a straightforward regi path, could be $3B at peak. RBC remain buyers.

nUme22 Posted - 02/29/24

$JANX $LBPH $PLRX easy to see.. drop will be slow and gradual ..

Oversold_Gems Posted - 02/28/24

$PLRX

Stock_Titan Posted - 02/27/24

$PLRX Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results https://www.stocktitan.net/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-fourth-nnzit1axlj3w.html

nUme22 Posted - 1 month ago

$JANX guranted offering.. But public offering at a high price. and worse, post offering the SP wont go down easily.. Artifically it will be inflated to high SP for some time before this loses steam. Highly manipulated like $PLRX, $LBPH etc

Stock_Titan Posted - 2 months ago

$PLRX Pliant Therapeutics to Participate in Upcoming Investor Conferences https://www.stocktitan.net/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-i7dl52adpx3z.html

StockInvest_us Posted - 2 months ago

Signal alert: $PLRX - Oversold Trend Short (Undervalued) https://stockinvest.us/l/tEYWt1H439

Stock_Titan Posted - 2 months ago

$PLRX Pliant Therapeutics to Participate in Upcoming Investor Events https://www.stocktitan.net/news/PLRX/pliant-therapeutics-to-participate-in-upcoming-investor-s6fhvsaol2yj.html

nUme22 Posted - 2 months ago

$FDMT it won’t go down now.. it will take 2-3 months .. ala $PLRX It will go down even with good news then

AnaChart Posted - 2 months ago

$PLRX https://anachart.com/wp-content/uploads/ana_temp/1707159704_soc-img.jpg

xbibackto70s Posted - 2 months ago

$PLRX bios are fun

nUme22 Posted - 2 months ago

$PLRX tutes done artificially propping this or what ?

piano91 Posted - 2 months ago

$PLRX Bought a chunk here still beats primary and secondary goals. I see no big risks here

bullwink Posted - 2 months ago

$PLRX Geez. what is going on this morning?

CL0WNsHalvingShort Posted - 2 months ago

$PLRX Up almost 30% in Germany. I’ll be taking a position in this for a run based on the positive news

CL0WNsHalvingShort Posted - 2 months ago

$CHEA $EYPT $MEGL $PLRX Eyepoint not moving in Germany. Pliant up 25%.

AlertsAndNews Posted - 2 months ago

Happy sunday! Time to get ready for a New week, Sunday Watchlist and Review is ready to roll. Headlines this weekend on $PLRX $EYPT $HOLI, and that's just scratching the surface. Last week $RVSN $MINM were some amazing plays! Enjoy the read! https://alertsandnews.com/weekly-watchlist-and-review-2-4-24/

CL0WNsHalvingShort Posted - 2 months ago

$CHEA Rebranding and lock up agreement removed. Insiders can dump on us. Expect a pump on the rebranding vote...then a dump by insiders. Play it safe.... $PLRX Primary and Secondary endpoints met. "Topline data " was not used. This can pump 100%. Will see how it opens in Germany. $EYPT Primary endpoint met. Topline results. This can also pump 100%. Will see how it opens in Germany. $MEGL If it takes out 1.10 then we are good to go. Happy Monday!

DonCorleone77 Posted - 2 months ago

$PLRX 3 of 3 - Pliant Therapeutics announces data from INTEGRIS-PSC Phase 2a trial ....of bexotegrast relative to placebo. Patients in the trial who had concomitant inflammatory bowel disease saw no change in their IBD symptoms as measured by partial Mayo Score while on treatment. Consistent with the lower doses tested, bexotegrast at 320 mg reduced ELF score relative to placebo at Week 12. The ELF score is a well-established prognostic marker of liver disease severity and liver-related events in patients with advanced fibrosis. ELF is strongly associated with transplant-free survival in PSC and may be useful as a surrogate marker in clinical trials. Consistent with the lower doses tested, bexotegrast at 320 mg reduced PRO-C3 levels relative to placebo. PRO-C3 is a biomarker of active fibrogenesis with higher levels associated with greater disease activity. The Company is planning to share these data from the INTEGRIS-PSC trial with regulatory authorities....

DonCorleone77 Posted - 2 months ago

$PLRX 2 of 3 - Pliant Therapeutics announces data from INTEGRIS-PSC Phase 2a trial ....bexotegrast-treated patients at the 320 mg dose showed a reduction in both ELF score and PRO-C3 levels relative to placebo at Week 12. Bexotegrast-treated patients also showed stabilization of alkaline phosphatase levels, relative to an increase on placebo at Week 12. In addition, MRI imaging continued to show evidence of improved hepatocyte function and bile flow with bexotegrast at the 320 mg dose relative to placebo. Bexotegrast at the 320 mg dose was well tolerated with no dose relationship observed for adverse events. Of the 27 patients treated with bexotegrast at the 320 mg dose, 26 completed 12 weeks of treatment with no drug-related severe or serious adverse events. Most treatment-emergent adverse events were mild or moderate in severity and consistent with PSC disease symptoms. In addition, adverse events of pruritus and cholangitis occurred less frequently on all doses....

DonCorleone77 Posted - 2 months ago

$PLRX 1 of 3 - Pliant Therapeutics announces data from INTEGRIS-PSC Phase 2a trial Pliant Therapeutics announced 12-week interim data from the 320 mg dose group of INTEGRIS-PSC, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis and suspected moderate to severe liver fibrosis. The 320 mg group met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period and its plasma concentrations increased with dose. There was no dose relationship for adverse events. Pruritus and cholangitis occurred less frequently on bexotegrast than on placebo. The trial's exploratory efficacy endpoints assessed changes in the liver fibrosis markers, Enhanced Liver Fibrosis score and PRO-C3 levels, as well as liver biochemistry and magnetic resonance imaging of the liver. Consistent with the results from the lower doses tested....

tickeron Posted - 3 months ago

$PLRX 5 Insiders at Pliant Therapeutics sold 60,780 shares last week for $1.0M https://srnk.us/go/4975329

macroaxis Posted - 3 months ago

$PLRX - Sale by Hull Hans of 9786 shares of Pliant TherapeuticsInc - Pliant TherapeuticsInc https://www.macroaxis.com/invest/story/PLRX/30296046/Sale-by-Hull-Hans-of-9786-shares-of-Pliant-TherapeuticsInc #insidertrading #stocks #fintechnews

MarketBeatInsiderTrades Posted - 3 months ago

Pliant Therapeutics General Counsel Mike Ouimette Sells $89,544.31 in $PLRX www.marketbeat.com/stocks/NASDAQ/PLRX/insider-trades/

MarketBeatInsiderTrades Posted - 3 months ago

Pliant Therapeutics CEO Bernard Coulie Sells $443,172.83 in $PLRX www.marketbeat.com/stocks/NASDAQ/PLRX/insider-trades/